News & Updates

In a phase I/II study, the novel T-cell-engaging bispecific antibody glofitamab bares its potential for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).

New drug applications approved by US FDA as of 01-15 February 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Consuming high amounts of meat products appears to contribute to an increased risk of developing coronary heart disease in Korean men, according to a study.

A recent study has strengthened the view that childhood maltreatment contributes to mental health problems. In addition, findings suggest wider genetic and environmental risk factors mediate part of the overall mental health problem risk in those exposed to maltreatment.

Mandatory training of healthcare professionals (HCPs) for the safe handling of cytotoxic drugs (CDs) conducted by a qualified oncology-pharmacist results in a decrease in the hazardous effects of CDs, reports a study.

Among Chinese patients with acute ischaemic stroke, intravenous (IV) tenecteplase is noninferior to the standard-of-care alteplase in achieving an excellent functional outcome, with a similar safety profile, when given within 4.5 hours of symptom onset, according to the TRACE-2* trial presented at ISC 2023.